Lifetime Risks, Projected Numbers, and Adverse... : Chest (original) (raw)
Original Research: Cardiovascular Disease
Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation
A Report From the Taiwan Nationwide AF Cohort Study
- Tze-Fan Chao
- Chia-Jen Liu
- Ta-Chuan Tuan
- Tzeng-Ji Chen
- Ming-Hsiung Hsieh
- Gregory Y.H. Lip
- Shih-Ann Chen
Chest
153
(
2
)
:p
453
-
466
,
February 2018
.
| DOI: 10.1016/j.chest.2017.10.001
Background
Most data on the clinical epidemiology of atrial fibrillation (AF) come from Western populations, and data for Asians are limited. We investigated the lifetime risk and projected number of AF among Asians. The annual risks of adverse events among patients with AF, time trends, and the risks compared with patients without AF were analyzed.
Methods
Between 2000 and 2011, 289,559 patients aged ≥ 20 years experienced new-onset AF in Taiwan. The incidence, prevalence, and lifetime risk of AF were calculated. The risk of adverse events among patients with AF were analyzed and compared with that of age- and sex-matched patients without AF.
Results
The incidence of AF in year 2011 was 1.51 per 1,000 person-years, with a lifetime risk of AF being appropriately 1 in 7 for subjects aged > 20 years. The prevalence of AF is estimated to be 4.01% in 2050. Compared with patients without AF, AF was associated with an increased risk of mortality (adjusted hazard ratio [aHR], 2.61), heart failure (aHR, 3.31), ischemic stroke (aHR, 3.34), dementia (aHR, 1.56), sudden cardiac death (aHR, 1.83), and myocardial infarction (aHR, 1.62); all P < .01. The risks of ischemic stroke, heart failure, and mortality were especially higher compared with patients without AF in the initial period (approximately 6 months) after AF was first diagnosed.
Conclusions
The burden of AF among Asian patients is increasing, with a lifetime risk of AF being 1 in 7. Optimized management of any associated comorbidities should be part of the holistic management approach for AF.
Copyright © 2018Elsevier, Inc.